Parataxis Korea, Inc. (KOSDAQ:288330)

South Korea flag South Korea · Delayed Price · Currency is KRW
416.00
-13.00 (-3.03%)
At close: Apr 7, 2026
Market Cap44.13B -82.9%
Revenue (ttm)9.00M +313.2%
Net Income-31.00B
EPS-445.00
Shares Out106.08M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,270,537
Average Volume1,425,087
Open432.00
Previous Close429.00
Day's Range392.00 - 557.00
52-Week Range392.00 - 9,280.00
Beta2.03
RSI31.02
Earnings DateMar 27, 2026

About Parataxis Korea

Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomw... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 21
Stock Exchange KOSDAQ
Ticker Symbol 288330
Full Company Profile

Financial Performance

In 2025, Parataxis Korea's revenue was 9.00 million, an increase of 313.21% compared to the previous year's 2.18 million. Losses were -31.00 billion, 56.9% more than in 2024.

Financial Statements